Document Detail


Transient leukoencephalopathy after intrathecal methotrexate mimicking stroke.
MedLine Citation:
PMID:  21243392     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Methotrexate (MTX) is an indispensable antimetabolite for the treatment of oncological and immunological disorders in all age groups. It can be administrated intravenously as well as intrathecally and may be used alone or in combination with other drugs. Chronic leukoencephalopathy is a well-known side effect of MTX, especially in conjunction with intrathecal administration. However, acute neurotoxicity with confusion, disorientation, seizures, and focal deficits may also be seen. This can clinically mimic stroke with restricted diffusion on MRI. However, unlike stroke, there is resolution of clinical and imaging findings within 1-4 weeks. We report two cases of transient leukoencephalopathy following intrathecal methotrexate, with complete clinical and radiological resolutions on follow-up.
Authors:
Amit Agarwal; Kanupriya Vijay; Krishnamoorthy Thamburaj; Tao Ouyang
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-1-18
Journal Detail:
Title:  Emergency radiology     Volume:  -     ISSN:  1438-1435     ISO Abbreviation:  -     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-1-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9431227     Medline TA:  Emerg Radiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Radiology, Penn State University, Hershey Medical Center, 500 University Drive, Hershey, PA, 17036, USA, aagarwal1@hmc.psu.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An Autolytic Process for Recovery of Antioxidant Activity Rich Carotenoprotein from Shrimp Heads.
Next Document:  Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of t...